Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir
- 1 October 1998
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 42 (10), 2637-2644
- https://doi.org/10.1128/aac.42.10.2637
Abstract
Nelfinavir mesylate (formerly AG1343) is a potent and selective inhibitor of human immunodeficiency virus (HIV) protease approved for the treatment of individuals infected with HIV. Nucleotide sequence analysis of protease genes from plasma HIV type 1 (HIV-1) RNA revealed a unique aspartic acid (D)-to-asparagine (N) substitution at residue 30 (D30N) in 25 of 55 patients treated with nelfinavir for a median of 13 weeks. Although the appearance of D30N was occasionally associated with concurrent or sequential emergence of other changes (e.g., at residues 35, 36, 46, 71, 77, and 88), genotypic changes associated with phenotypic resistance to other protease inhibitors were not observed (e.g., at residues 48, 50, 82, and 84) or were only rarely observed (e.g., at residue 90). In phenotypic assays, viral isolates with high-level resistance to nelfinavir remained susceptible to indinavir, saquinavir, ritonavir, and amprenavir (formerly VX-478/141W94). Similar results were observed in phenotypic assays utilizing HIV-1 NL4-3, which contained the D30N substitution alone or in combination with substitutions at other residues (e.g., residues 46, 71, and 88). These data indicate that the initial pathway of resistance to nelfinavir is unique and suggest that individuals failing short courses of nelfinavir-containing regimens may respond to regimens containing other protease inhibitors.Keywords
This publication has 30 references indexed in Scilit:
- Viracept (Nelfinavir Mesylate, AG1343): A Potent, Orally Bioavailable Inhibitor of HIV-1 ProteaseJournal of Medicinal Chemistry, 1997
- Mutational Anatomy of an HIV-1 Protease Variant Conferring Cross-resistance to Protease Inhibitors in Clinical TrialsPublished by Elsevier BV ,1996
- In Vivo Resistance to a Human Immunodeficiency Virus Type 1 Proteinase Inhibitor: Mutations, Kinetics, and FrequenciesThe Journal of Infectious Diseases, 1996
- Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and ZalcitabineNew England Journal of Medicine, 1996
- Structural Mechanisms of HIV Drug ResistanceAnnual Review of Pharmacology and Toxicology, 1996
- Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4 + lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivityAntiviral Research, 1996
- Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538)AIDS, 1996
- Three-dimensional Structure of a Mutant HIV-1 Protease Displaying Cross-resistance to All Protease Inhibitors in Clinical TrialsPublished by Elsevier BV ,1995
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995
- STRUCTURE-BASED INHIBITORS OF HIV-1 PROTEASEAnnual Review of Biochemistry, 1993